Colonis launches first licensed product - Aviticol

Quantum Pharma Plc

("Quantum", the "Company" or the "Group")

Colonis launches first licensed product - Aviticol

Quantum Pharma Plc (AIM: QP), a growing manufacturer, supplier and service provider to the niche pharmaceutical sector, announces that its wholly owned subsidiary Colonis Pharma Limited ("Colonis"), a specialist pharmaceutical product development business, which focuses on achieving regulated status for medicines and medical devices, has today launched its first licensed product, Aviticol 20 000IU Capsules after having received the granting of its UK Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency ("MHRA"). This product contains cholecalciferol 500mcg for the treatment and prevention of vitamin D deficiency in adults and adolescents.

The award of a Marketing Authorisation for Aviticol 20 000IU Capsules and its launch marks a significant milestone for Colonis and follows on from the product receiving Approvable status from the MHRA on 13 November 2014. Current annual sales in the UK of the unlicensed versions of these products are estimated at over £8 million and Colonis now has the ability to gain a significant share of that market through its licensed product.

Once a medicine has been granted a licence and stock is available to satisfy orders, all Specials manufacturers must stop supplying that medicine as a Special, all prescribers should prescribe the licensed version and pharmacies should source the licensed product from a licence holder.

Quantum's knowledge of the Specials market, combined with Colonis' product development and regulatory pathway expertise, enables the Group to track shifts in demand for products across the community pharmacy and hospital pharmacy markets and to identify which products will be best suited to be taken through the development programme and meet patients' needs.

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "Today sees the launch of our first licensed product to come through Colonis' exciting development programme. Vitamin D deficiency has been linked to increased risk of asthma attacks, treatment of certain types of cancer and chronic pain prevention and, as such, we anticipate Aviticol 20 000IU Capsules to receive strong demand in a growing market.

"Colonis' future pipeline is robust, with a further 30 products across 15 therapeutic areas which we aim to move through to licensed status over the next 24 months. In addition, we will continue to introduce new projects into the pipeline.

"We believe that Colonis represents the Group's most significant growth opportunity, with new products having the potential to generate substantial income for Quantum annually, once they have received the relevant regulated status from the MHRA."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a growing manufacturer, supplier and service provider to the wholesale and retail pharmacy, hospital, homecare and care home markets. Based in a purpose-built facility in Burnopfield, County Durham, the Group manufactures and sources non-standard pharmaceutical products. Formed in 2004, Quantum has grown significantly in recent years (both organically and by acquisition) and now employs over 320 people. The Group operates through five business units.

Quantum Pharmaceutical, the Group's core business, manufactures and supplies Specials and Special Obtains to the majority of the large retail pharmacy chains and pharmaceutical wholesalers in the UK, hospitals, independent pharmacies and dispensing doctors. Specials and Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from wholesale pharmacy suppliers. Quantum has a product range of over 22,000 Special and Special Obtain products. It regularly services around 6,500 pharmacies and over 240 hospital accounts across the UK.

U L Medicines ("ULM") is a supplier of unlicensed imports (over 450 imported medicines), over 100 batch made Specials and bespoke Specials with a focus on the hospital market. ULM has a diverse customer base and supplies over 240 hospital accounts, as well as wholesalers and retail pharmacies in the UK and wholesalers overseas.

Colonis is a specialist pharmaceutical product development business, which focuses on achieving the relevant regulated status for medicines and medical devices. The development programme is currently working on a significant pipeline of products across 15 therapeutic areas.

Biodose is a patent protected medicine delivery system ("MDS") which consists of a tray, 28 medication pods and a seal, which is used to manage pre-prepared medication regimes for patients. These assist with patient specific medicine administration and adherence to medication regimes. The Biodose system is currently sold to around 175 pharmacy customers, through whom around 50,000 care home residents use Biodose.

Quantum Aseptics' facility at Burnopfield became operational in April 2013 after receiving an MHRA aseptic special manufacturing licence. This facility, which the Director's believe to be is one of the most advanced aseptics units in the UK, provides Quantum Aseptics (a division of Quantum Pharmaceutical) with the ability to aseptically prepare and supply intravenous dosage form aseptic products, whilst complementing the existing core business product offering by providing the ability to prepare these sterile Specials for the Group's other business units and third parties.

For further information, please visit www.quantumpharmaplc.com.